Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Context: The film opens with narration over a silhouette of Hill House at night. The narrator, Dr. John Markway (Richard Johnson) tells us, "An evil old house, the kind some people call haunted is like an undiscovered country waiting to be explored. Hill House had stood for 90 years and might stand for 90 more. Silence lay steadily against the wood and stone of Hill House. Whatever walked there walked alone." Title and credits follow, then narration continues, "Scandal, murder, insanity, suicide: The history of Hill House was ideal. It had everything I wanted..." The house was built in New England by a man named Hugh Crain for his wife and young daughter. A horse and carriage accident took the life of the first Mrs. Crain (an uncredited Pamela Buckley) before she even saw the house. Hugh Crain (an uncredited Howard Lang) and young daughter, Abigail (an uncredited Janet Mansell) said a few words over the body, but Hugh was left an embittered man. Crain married again, and the second Mrs. Crain (an uncredited Freda Knorr) also died, falling down the main staircase. Hugh Crain left Abigail with a nurse (an uncredited Susan Richards) and went to England where he died in a drowning accident. Abigail kept the same nursery room her entire life. By the time she was eighty (an uncredited Amy Dalby) she was a bedridden invalid. Her nurse-companion (an uncredited Rosemary Dorken) was a local girl and, it is with this young companion the evil reputation of Hill House really begins. The old lady died while calling for help. The companion was trysting on the verandah with a farm hand. The companion inherited Hill House and occupied it for many years, but eventually hanged herself. The house then passed to a distant relative, named Mrs. Sanderson (Fay Compton).Markway visits Mrs. Sanderson where he convinces her to let him use the house for psychic research. He explains, "I shall occupy the house with a group of carefully selected assistants...I must have specially qualified help to take notes and document any evidence of the supernatural I may find." Eldridge Harper (Ronald Adam), Mrs. Sanderson's lawyer, voices his concern about publicity seekers and the propriety of having women in the house. Harper suggests to Mrs. Sanderson that her nephew, Luke, joins the doctor at Hill House, as he expects to inherit the property. Mrs. Sanderson asks point blank, "Exactly what do you and your assistants expect to find at Hill House?" Markway replies, "Maybe only a few loose floorboards, and maybe, I only say maybe, the key to another world."Dr. Markway, taking a leave of absence from his university professorship, finalizes his list of assistants. Only two end up accepting, Eleanor Lance and Theodora (no last name).Eleanor Lance (Julie Harris) is living with her sister. She is nearly broke and weary after looking after her invalid mother non-stop for eleven years. Mother is now dead, and she fights with her sister over just about everything. She begs to use the car, which is after all, half hers. Her brother-in-law, Bud Fredericks (an uncredited Paul Maxwell) tries to act as mediator between Eleanor and his wife, Carrie (Diane Clare). He is sympathetic to Eleanor's plight, but their daughter, Dora (an uncredited Verina Greenlaw) takes her cues from her mother, and taunts her Aunt Eleanor. On the vacation plan, Bud sides with Eleanor, "I think you should have a vacation, Nell." Carrie objects, but Eleanor is not to be deterred and she shows her family how she reacts when pushed to her breaking point. She is normally quiet and meek, but when pushed is loud and assertive.Nell decides to take the car and confronts the garage attendant (an uncredited Claude Jones) for the keys. She departs Boston along U.S. 50 and Route 238 to Hill House. We hear Nell thinking and she reveals she will never return to live with her sister. In fact, most of what we learn of Eleanor is hearing her thoughts.Eleanor 
 Question: What is the ghost's name?
hugh crain

Context: It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades. 
 Question: What is the target of tanezumab?
ngf

Context: Selexipag is a first-in-class orally available selective non-prostanoid IP receptor agonist. This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH). Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized. In addition, the selexipag metabolite has a half-life of 7.9 h, thus permitting oral dosing twice daily. Selexipag showed effects on pharmacodynamic end points obtained with right heart catheterization in a Phase II trial in patients with PAH, and is being evaluated in the ongoing Phase III trial (GRIPHON trial, Clinicaltrials.gov NCT01106014). The signal of a beneficial effect of selexipag on disease progression may become more robust for long term under prolonged exposure. Pending the GRIPHON trial results, selexipag could provide a convenient first-line prostacyclin treatment option for patients with PAH. 
 Question: Selexipag is used for which disease?

pulmonary arterial hypertension